Abstract: The present invention relates to a ?9 desaturase, which has the ability to convert palmitic acid [16:0] or stearic acid [18:0] into palmitoleic acid [16:1] or oleic acid [18:1], respectively. Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding ?9 desaturase along with a method of making long chain polyunsaturated fatty acids (PUFAs) using this ?9 desaturase in oleaginous yeast is disclosed.

Abstract: The present invention relates to ?9 elongases, which have the ability to convert linoleic acid (LA; 18:2 ?-6) to eicosadienoic acid (EDA; 20:2 ?-6) and/or ?-linolenic acid (ALA; 18:3 ?-3) to eicosatrienoic acid (ETrA; 20:3 ?-3). Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding ?9 elongases along with a method of making long-chain polyunsaturated fatty acids (PUFAs) using these ?9 elongases in oleaginous yeast are disclosed.

Abstract: The present invention relates to ?8 desaturase genes, which have the ability to convert eicosadienoic acid (EDA; 20:2 ?-6) to dihomo-?-linolenic acid (DGLA; 20:3 ?-6) and/or eicosatrienoic acid (ETrA; 20:3 ?-3) to eicosatetraenoic acid (ETA; (20:3 ?-3). Isolated nucleic acid fragments and recombinant DNA constructs comprising such fragments encoding ?8 desaturases along with a method of making long-chain polyunsaturated fatty acids (PUFAs) using these ?8 desaturases in oleaginous yeast are disclosed.

Abstract: The present invention relates to a ?12 fatty acid desaturase able to catalyze the conversion of oleic acid to linoleic acid (LA; 18:2). Nucleic acid sequences encoding the desaturase, nucleic acid sequences that hybridize thereto, DNA constructs comprising the desaturase gene, and recombinant host microorganisms expressing increased levels of the desaturase are described. Methods of increasing production of specific ?-3 and/or ?-6 fatty acids are described by overexpression of the ?12 fatty acid desaturase or by disruption of the native gene.

Abstract: The present invention provides a microorganism useful for biologically producing 1,3-propanediol from a fermentable carbon source at higher yield than was previously known. The complexity of the cofactor requirements necessitates the use of a whole cell catalyst for an industrial process that utilizes this reaction sequence to produce 1,3-propanediol. The invention provides a microorganism with disruptions in specified genes and alterations in the expression levels of specified genes that is useful in a higher yielding process to produce 1,3-propanediol.

Abstract: The present invention relates to mutant ?8 desaturase genes, which have the ability to convert eicosadienoic acid [20:2 ?-6, EDA] to dihomo-?-linolenic acid [20:3, DGLA] and/or eicosatrienoic acid [20:3 ?-3, ETrA] to eicosatetraenoic acid [20:3 ?-3, ETA]. Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding ?8 desaturase along with methods of making long-chain polyunsaturated fatty acids (PUFAs) using these mutant ?8 desaturases in plants and oleaginous yeast are disclosed.

Abstract: The present invention relates to a ?5 desaturase, which has the ability to convert dihomo-?-linolenic acid (DGLA; 20:3 ?-6) to arachidonic acid (ARA; 20:4 ?-6) and/or eicosatetraenoic acid (ETA; 20:4 ?-3) to eicosapentaenoic acid (EPA; 20:5 ?-3). Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding ?5 desaturase along with a method of making long chain polyunsaturated fatty acids (PUFAs) using this ?5 desaturase in oleaginous yeast are disclosed.

Abstract: The present invention relates to a ?5 desaturase, which has the ability to convert dihomo-?-linolenic acid (DGLA; 20:3 ?-6) to arachidonic acid (ARA; 20:4 ?-6) and/or eicosatetraenoic acid (ETA; 20:4 ?-3) to eicosapentaenoic acid (EPA; 20:5 ?-3). Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding ?5 desaturase along with a method of making long chain polyunsaturated fatty acids (PUFAs) using this ?5 desaturase in oleaginous yeast are disclosed.

Abstract: The present invention relates to ?9 elongases, which have the ability to convert linoleic acid [18:2, LA] to eicosadienoic acid [20:2, EDA]. Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding ?9 elongase along with methods of making long-chain polyunsaturated fatty acids (PUFAs) using these ?9 elongases in plants and oleaginous yeast are disclosed.

Abstract: Avidin-binding azo reagents which alter the spectrophotometric properties of avidin and the use of such reagents in homogeneous assays are described.

Abstract: A method to assist in the diagnosis of Alzheimer's disease comprising detecting, in bodily fluids, two APP-related proteins, in soluble form, said proteins have an apparent molecular size of about 130 kDa and about 35 kDa, and each of said proteins shares at least one epitope with the C-terminus of APP corresponding substantially to amino acids 676-695 of APP as shown in FIG. 1.

Abstract: The present invention concerns a plasticized polyvinyl alcohol release composition for an aqueous or semi-aqueous processible flexographic printing plate comprising:(a) at least 60% of a substantially hydrolyzed polyvinyl alcohol based on the total weight of the release composition; and(b) at least 8% plasticizer, based on the total weight of the release composition.This invention also concerns aqueous or semi-aqueous processible flexographic photosensitive elements containing this plasticized polyvinyl alcohol release layer and to processes for making printing reliefs from such elements.

Abstract: Monoclonal antibodies reactive with oncogenic and activated ras p21 proteins containing aspartic acid or valine at position 13 and unreactive with normal ras p21 proteins containing glycine at position 13. The antibodies are secreted by hybridomas obtained by immunizing mice with synthetic peptides corresponding in amino acid sequence to positions 5-9 of normal ras p21 proteins, except having aspartic acid in place of glycine at position 13 and except for the addition of cysteine at the amino terminal end of the peptide. The antibodies and immunoreactive fragments are useful in the classification of malignant and premalignant lesions.